IOVANCE PRESENTS NEW DATA AT ESMO 2026 DEMONSTRATING DEEP, DURABLE RESPONSES WITH LIFILEUCEL TIL CELL THERAPY PLUS PEMBROLIZUMAB IN FRONTLINE ADVANCED MELANOMA

Reuters · 2d ago

Please log in to view news